# Avicanna Subsidiary Achieves First Commercial Export of CBG Cultivar to Australia > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/minor-cannabinoids-clinical-research-cbg-export-australia/ > **Published:** 2026-03-26T21:03:27-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:04-04:00 > **Clinical Summary:** Explore minor cannabinoids clinical research with Avicanna's first commercial export of CBG cultivar to Australia, highlighting emerging therapeutic potential. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic CbgMinor CannabinoidsInternational TradeEmerging Therapeutics[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) Why This Matters The commercial availability of CBG-dominant cultivars represents an expansion of minor cannabinoid access for clinical use. CBG shows distinct pharmacological properties from THC and CBD, potentially offering different therapeutic profiles for conditions like inflammatory bowel disease and glaucoma. Clinical Summary Avicanna’s subsidiary has completed the first commercial export of a cannabigerol (CBG)-dominant cannabis cultivar to Australia. CBG is a minor cannabinoid that serves as the precursor to THC and CBD, typically present in very low concentrations in mature cannabis plants. Early research suggests CBG may have anti-inflammatory, antibacterial, and neuroprotective properties, though clinical evidence remains limited. This export milestone indicates growing international interest in minor cannabinoids beyond the traditional THC/CBD paradigm. Dr. Caplan’s Take “While CBG research is intriguing, we’re still in the early stages of understanding its clinical utility. I’m watching for real-world patient data as these products become more accessible, but clinicians should maintain appropriate skepticism about minor cannabinoid claims until we have robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/).” Clinical Perspective 🧠 Clinicians should be aware that patients may increasingly ask about CBG products as they become commercially available. Current evidence is largely preclinical, so standard counseling about experimental therapies applies. Monitor for any unique side effects or interactions as clinical experience with isolated CBG grows. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Avicanna%20subsidiary%20SMGH%20completes%20first%20commercial%20export%20of%20CBG%20cultivar%20to%20Au...%20%40drcaplan&url=https%3A//stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Avicanna%20subsidiary%20SMGH%20completes%20first%20commercial%20export%20of%20CBG%20cultivar%20to%20Au...%20--%20via%20%40drcaplan.bsky.social%20https%3A//stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/](https://stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/) Table of Contents - [FAQ](#FAQ)[What is CBG and why is it significant?](#What_is_CBG_and_why_is_it_significant) - [What makes this a notable clinical development?](#What_makes_this_a_notable_clinical_development) - [How do minor cannabinoids differ from major ones?](#How_do_minor_cannabinoids_differ_from_major_ones) - [What role does international trade play in cannabinoid development?](#What_role_does_international_trade_play_in_cannabinoid_development) - [Why are emerging therapeutics in cannabis medicine important?](#Why_are_emerging_therapeutics_in_cannabis_medicine_important) - [Related](#Related) ## FAQ #### What is CBG and why is it significant? CBG (cannabigerol) is a minor cannabinoid that serves as a precursor to other cannabinoids like THC and CBD. It’s gaining attention for its potential therapeutic properties and is considered an emerging therapeutic compound in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/). #### What makes this a notable clinical development? This development has been rated #70 for clinical relevance, indicating it represents emerging findings or policy developments worth monitoring closely. The classification suggests it has notable clinical interest for healthcare professionals. #### How do minor cannabinoids differ from major ones? Minor cannabinoids like CBG are found in smaller concentrations compared to major cannabinoids like THC and CBD. However, they’re increasingly recognized for their unique therapeutic potential and may offer distinct medical benefits. #### What role does international trade play in cannabinoid development? International trade regulations and policies significantly impact the research, development, and availability of cannabinoid-based therapeutics. Global market access and regulatory harmonization are crucial for advancing [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/). #### Why are emerging therapeutics in cannabis medicine important? Emerging cannabis therapeutics represent new treatment options that could address unmet medical needs. As research progresses, these compounds may provide alternative or complementary therapies for various health conditions. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Avicanna subsidiary SMGH completes first commercial export of CBG cultivar to Australia”, “url”: “https://stratcann.com/news/avicanna-subsidiary-smgh-completes-first-commercial-export-of-cbg-cultivar-to-australia/”, “datePublished”: “2026-03-27T00:36:57Z”, “about”: “avicanna subsidiary smgh completes first commercial”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The Rise of Minor Cannabinoids: How CBN and THCv Are Becoming Cannabis's Next Big …](https://cedclinic.com/cbn-thcv-appetite-suppression-evidence-minor-cannabinoids/) Explore how minor cannabinoids like CBN and THCv are gaining attention for their unique therapeutic properties and clinical potential. [Read More](https://cedclinic.com/cbn-thcv-appetite-suppression-evidence-minor-cannabinoids/) [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) An in-depth look at various cannabinoids and their emerging roles in clinical patient care and therapeutic applications. [Explore Now](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) [Many studies show the efficacy of cannabis for inflammation. That's important because …](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) Review clinical evidence supporting cannabis's [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/), relevant to minor cannabinoids like CBG. [Learn More](https://cedclinic.com/cannabis-anti-inflammatory-effects-research-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).